<DOC>
	<DOCNO>NCT01999231</DOCNO>
	<brief_summary>In test , small sample clinical study Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 ( Recombination EC Allergen） healthy adult carry . 24 healthy adult include study object , randomly divide four group different Recombinant Allergen EC dose ( 1 , 5 , 10μg/mL , maximum tolerate dose 20μg/mL , 6 person/dose ) single arm intradermal injection . The main examination item : vital sign ( breathe , heart rate , blood pressure , body temperature ) volunteer 15min , 30min , 1h , 2h , 4h , 8h , 24h , 48h , 72h , 96h injection , skin reactivity ( redness and/or induration ) diameter injection site , local reaction ( rash , pain , itching , skin mucous membrane ) , variety adverse event , routine blood , routine urine , liver kidney function , ECG chest X-ray film 7 day intradermal injection . Preliminary evaluation safety tolerability Recombinant Allergen EC apply human , provide safe dosage range phase II clinical study .</brief_summary>
	<brief_title>Phase I Clinical Human Tolerability Study Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10</brief_title>
	<detailed_description>This clinical study adopts open , randomize study method carry Recombinant EC Allergen small sample healthy adult . 24 healthy adult include study object , randomly divide four group different Recombinant EC Allergen dose ( 1 , 5 , 10μg/mL , maximum tolerate dose 20μg/mL , 6 person/dose ) single arm intradermal injection , set two people replacement group ( one male one female ) . Intradermal injection one third site healthy subject ' leave right forearm palmaris 0.1ml Recombinant EC Allergen one time . The main examination item : vital sign ( breathe , heart rate , blood pressure , body temperature ) volunteer 15min , 30min , 1h , 2h , 4h , 8h , 24h , 48h , 72h , 96h injection , skin reactivity ( redness and/or induration ) diameter injection site , local reaction ( rash , pain , itching , skin mucous membrane ) , variety adverse event , routine blood , routine urine , liver kidney function , ECG chest X-ray film 7 day intradermal injection . In phaseⅠclinical study , person accept one dose , After injection dose volunteer group , sure next injection volunteer 40 minute interval . Different dose group : next dose test carry case serious adverse event appear 7days last one volunteer 's injection former low dose group . Statistical analysis perform use SAS9.3 software , analytic process routinization .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<criteria>Aged 18 40 year old , age difference 10 year old within batch healthy volunteer , male female ratio case 1:1 . Body mass index range 20 27 Body Mass Index BMI : weight ( Kg ) / height ( M2 ) ; Agreed participate test sign inform consent ; Subjects comply requirement clinical trial protocol follow ; Subjects history TB ( Tuberculosis ) family history tuberculosis ; People pulmonary tuberculosis extrapulmonary tuberculosis , respiratory symptom systemic symptom ; People tuberculosis focus examination Xray chest radiograph sputum bacillus ; Subjects acute chronic disease , acute infectious disease , dermatosis skin allergy cause various reason ; Physical condition : history heart , liver , kidney , gastrointestinal tract , nervous system , metabolic disturbance , etc . ECG , blood pressure , heart rate , respiratory status lab test index include blood , urine , liver kidney function , etc normal within 4 week screen ; No close contact tuberculosis ; Subjects participate clinical drug trial inoculate prophylactic immune globulin nearly 3 month ; Temperature normal ; Stop smoking , drink drinking contains caffeinated . Health people close contact TB ( Tuberculosis ) patient , especially excreter 3 week selection ; Suffering serious disease , e.g . cancer treatment , autoimmune disease , progressive atherosclerosis , diabetes accompanied complication , chronic obstructive pulmonary disease ( COPD ) need oxygen therapy , acute progressive liver kidney disease , congestive heart failure , etc . ; People history allergy , convulsion , epilepsy , cerebropathy , neurological symptom sign ; Patients impair abnormal immune function , e.g . patient treat immunosuppressor immunopotentiator , receive immunoglobulin preparation blood product plasma extraction outside gastrointestinal tract 3 month , human immunodeficiency virus related disease ; Acute febrile illness infection ; Taking part clinic trial ; Subjects participate clinical drug trial 3 month clinical test ; Allergic constitution , e.g . patient allergic history two kind drug food , drug component ; Substance abuse alcoholic ; Pregnant breast feed woman ; Mental physical disability ; Informed leaver ; Any case may influence test evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>ESAT6</keyword>
	<keyword>CFP10</keyword>
	<keyword>skin test</keyword>
	<keyword>diagnostic test</keyword>
</DOC>